Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroNexus Technologies, a neurotechnology company, and Philips Research have signed a joint research agreement to develop next-generation deep brain stimulation devices to improve the treatment of neurological diseases and psychiatric disorders.
Subscribe to our email newsletter
By combining Philips Research’s strengths in microelectronics, signal processing, ultra-low power system design and miniaturization with NeuroNexus Technologies’s expertise in micro-scale electrode design and fabrication, the two companies aim to show the technical feasibility of highly programmable and magnetic resonance imaging (MRI)-safe deep brain stimulation devices. Their initial research will aim to meet the functional requirements of a deep brain stimulation device for the treatment of Parkinson’s disease.
The joint research project aims to address these clinical needs, and will leverage Philips’ expertise in medical imaging and surgery planning with the aim of simplifying the implantation process and shortening the surgical procedure.
According to Philips, it will also contribute to making the entire device MRI compatible so that patients fitted with the implant are not barred from MRI scans. With its world-leading track record in neural micro-electrodes, NeuroNexus Technologies has key technology and knowledge for novel brain probes.
Daryl Kipke, CEO of NeuroNexus, said: “With our micro-scale implantable electrode technology and Philips Research’s integration expertise, we are well positioned to make a significant leap forward in delivering technologies that will support neurologists and neurosurgeons in improving patient treatment.”